On May 8, 2025, HAYA Therapeutics, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, announced that the company has raised $65 million in Series A funding. The round was led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli Lilly, ATHOS, +ND Capital, Alexandria Venture Investments, and LifeLink Ventures, with additional support from existing investors. Wilson Sonsini Goodrich & Rosati advised HAYA Therapeutics on patent matters related to the transaction.

The financing will accelerate the clinical development of HAYA’s lead long non-coding RNA (lncRNA) targeting candidate HTX-001 in heart failure and the continued expansion of its RNA-guided regulatory genome pipeline development engine.

The Wilson Sonsini team that advised HAYA Therapeutics was led by Minyoung Shin and included Mike Hostetler, Jen Zeng, Esther Cynn, and Tiara Wong.

For more information, please see HAYA Therapeutics’ press release.